The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125474982 12547498 2 F 20150903 20160812 20160712 20160823 EXP JP-ROCHE-1791629 ROCHE 25.11 YR F Y 0.00000 20160823 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125474982 12547498 1 PS Omalizumab OMALIZUMAB 1 Subcutaneous 103976 450 MG SOLUTION FOR INJECTION
125474982 12547498 2 SS Omalizumab OMALIZUMAB 1 Subcutaneous 103976 450 MG SOLUTION FOR INJECTION
125474982 12547498 3 SS Omalizumab OMALIZUMAB 1 Subcutaneous 103976 450 MG SOLUTION FOR INJECTION
125474982 12547498 4 SS Omalizumab OMALIZUMAB 1 Subcutaneous 103976 450 MG SOLUTION FOR INJECTION
125474982 12547498 5 SS Omalizumab OMALIZUMAB 1 Subcutaneous 103976 450 MG SOLUTION FOR INJECTION
125474982 12547498 6 C FLUTIFORM FLUTICASONE PROPIONATEFORMOTEROL FUMARATE 1 Respiratory (inhalation) 500 UG, BID 0 500 UG BID
125474982 12547498 7 C SPIRIVA TIOTROPIUM BROMIDE MONOHYDRATE 1 Respiratory (inhalation) 5 UG, QD 0 5 UG QD
125474982 12547498 8 C THEO-DUR THEOPHYLLINE ANHYDROUS 1 Oral 200 MG, BID 0 200 MG BID
125474982 12547498 9 C TULOBUTEROL TULOBUTEROL 1 Transdermal 2 MG, QD 0 2 MG QD
125474982 12547498 10 C SINGULAIR MONTELUKAST SODIUM 1 Oral 10 MG, QD 0 10 MG QD
125474982 12547498 11 C ALLELOCK OLOPATADINE HYDROCHLORIDE 1 Oral 5 MG, BID 0 5 MG BID
125474982 12547498 12 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Oral 20 MG, UNK 0 20 MG
125474982 12547498 13 C SENNOSIDE SENNOSIDES 1 Oral 24 MG, UNK 0 24 MG
125474982 12547498 14 C AMITIZA LUBIPROSTONE 1 Oral 48 UG, UNK 0 48 UG
125474982 12547498 15 C MAGMITT MAGNESIUM OXIDE 1 Oral 990 MG, UNK 0 990 MG
125474982 12547498 16 C REFLEX MIRTAZAPINE 1 Oral 45 MG, UNK 0 45 MG
125474982 12547498 17 C DESYREL TRAZODONE HYDROCHLORIDE 1 Oral 100 MG, UNK 0 100 MG
125474982 12547498 18 C SILECE FLUNITRAZEPAM 1 Oral 2 MG, UNK 0 2 MG
125474982 12547498 19 C QUETIAPINE. QUETIAPINE 1 Oral 25 MG, UNK 0 25 MG
125474982 12547498 20 C BROTIZOLAM BROTIZOLAM 1 Oral 0.5 MG, UNK 0 .5 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125474982 12547498 1 Asthma
125474982 12547498 6 Asthma
125474982 12547498 7 Asthma
125474982 12547498 8 Asthma
125474982 12547498 9 Asthma
125474982 12547498 10 Asthma
125474982 12547498 11 Asthma
125474982 12547498 12 Gastrooesophageal reflux disease
125474982 12547498 13 Constipation
125474982 12547498 14 Constipation
125474982 12547498 15 Constipation
125474982 12547498 16 Depression
125474982 12547498 17 Schizophrenia
125474982 12547498 18 Insomnia
125474982 12547498 19 Schizophrenia
125474982 12547498 20 Insomnia

Outcome of event

Event ID CASEID OUTC COD
125474982 12547498 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
125474982 12547498 Asthma

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125474982 12547498 1 20150825 0
125474982 12547498 2 20150922 0
125474982 12547498 3 20151023 0
125474982 12547498 4 20151120 0
125474982 12547498 5 20151218 0